Gilead Sciences Inc. Gets First Hepatitis C Cocktail Drug Approved

October 10, 2014 10:33 PM

16 0

Perhaps the most anticipated Food and Drug Administration approval of the year has finally arrived. Today, the agency approved Gilead Sciences (NASDAQ: GILD ) Harvoni to treat hepatitis C.

Harvoni is special because it's the first cocktail that can rid patients with genotype 1 infection of the hepatitis C virus without the use of interferon, which has to be injected, and causes flu-like symptoms. The oral drug combines ledipasvir with Gilead Sciences' already-approved Sovaldi.

Read more

To category page